Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine (DTwP-Hib-HepB Vaccine) When Administered to Indian Infants at 6, 10, and 14 Weeks of Age

NCT01470287 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01470287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01470287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine (DTwP-Hib-HepB Vaccine) When Administered to Indian Infants at 6, 10, and 14 Weeks of Age
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
April 30, 2012
Enrollment
175 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, hemophilus influenzae b, hepatitis b, pertussis, tetanus